Bioventix Plc Director Dealing

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                               Director Dealing 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that the Company was notified on 26 April 2022 
that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, 
purchased a total of 3 ordinary shares of 5 pence each in the Company 
("Ordinary Shares"), at an average price of 3,500 pence per Ordinary Share (the 
"Purchase"). The shares were purchased under a dividend reinvestment plan 
(DRIP). 
 
Following the Purchase, Bruce Hiscock has a beneficial interest in 424 Ordinary 
Shares, representing approximately 0.01 per cent. of the issued share capital 
of the Company. 
 
The notification below, made in accordance with the requirements of the EU 
Market Abuse Regulation, provides further details. 
 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law 
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed 
in accordance with the company's obligations under Article 17 of MAR. 
 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
1       Details of the person discharging managerial responsibilities / person 
        closely associated 
 
a)      Name                     Bruce Hiscock 
 
2.      Reason for the Notification 
 
a)      Position/status          Chief Financial Officer 
 
b)      Initial notification/    Initial notification 
        Amendment 
 
3.      Details of the issuer, emission allowance market participant, auction 
        platform, auctioneer or auction monitor 
 
a)      Name                     Bioventix Plc 
 
b)      LEI                      213800225MHX7LZQY108 
 
4.      Details of the transaction(s): section to be repeated for (i) each type of 
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
        place where transactions have been conducted 
 
a)      Description of the       Ordinary Shares of 5 pence each 
        Financial instrument, 
        type of instrument 
 
        Identification code      GB00B4QVDF07 
 
b)      Nature of the            Purchase of Ordinary Shares 
        transaction 
 
c)      Price(s) and volume(s)   3 Ordinary Shares 
                                 3,500 pence 
 
d)      Aggregated information:  Purchase of 3 Ordinary Shares at 3,500 pence each 
 
        ·     Aggregated volume 
 
        ·     Price 
 
e)      Date of the transaction  25 April 2022 
 
f)      Place of the transaction London Stock Exchange, AIM Market (XLON) 
 
 
 
END 
 
 

(END) Dow Jones Newswires

April 26, 2022 07:50 ET (11:50 GMT)